Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>Events>This Event
  Events - February 2013

4th Cancer Targets and Therapeutics

25 Feb 2013 - 26 Feb 2013 - Las Vegas, NV, USA

Bookmark and Share

With the rapid progression of molecular biology and genetics, and the subsequent emergence of many new targets, emerging targets & therapeutics provides new opportunities for the prevention and treatment of several major disease systems. The 4th Cancer Targets & Therapeutics Conference, taking place on February 25-26, 2013 in Las Vegas, NV, examines new and emerging targets and therapeutics in the area of cancer research. Speakers at the event provide case studies in order to address some of the issues surrounding target-based drug discovery and development.

Preliminary Sessions for 2013 Agenda:

-Novel Kinase Inhibitors & Beyond the Kinome 

-Functional Genomics & Future Cancer targets 

-Novel Antibody-based Modalities 

-Progress in Cancer Immunotherapy

-Cancer Stem Cells, Metabolism, Cancer Epigenetics 

-Patient Selection Rationale & Strategy

This conference is part of our 2nd Novel Cancer Therapeutics Summit which consists of two other concurrent conferences shown below:

2nd Novel Cancer Therapeutics Summit:

Track: 4th Cancer Targets & Therapeutics

Track: 2nd Oncology Partnering & Deal-making

Track: 3rd Ubiquitin Research & Drug Discovery 

Sign up for the Summit Pass to have access to all tracks of the summit!

Call for Papers!

To be considered for an oral presentation, please submit an abstract here by January 25, 2013. Selected presentations will be based on quality of abstract and availability. Presentation slots fill up fast so please submit your abstract ASAP.

Sponsorship and exhibiting opportunities are available in a range of levels, which can be tailored to fit your needs. Please contact 626-256-6405 x102 or for more information.

Further information
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos